Clinical Trial

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Suspended Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
Per sponsor letter, due to a business decision based on reprioritization of their internal XmAb20717 programs, Xencor has determined that ECR003 activities must halt and no additional subjects may be enrolled
Summary
This phase II trial tests whether vudalimab works to shrink tumors in patients with anaplastic thyroid cancer or hurthle cell thyroid cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as vudalimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Protocol Amendment History 4 changes
critical Trial status changed: Active, Not Recruiting → Suspended 2026-08-15
critical Recruitment suspended: Per sponsor letter, due to a business decision based on reprioritization of their internal XmAb20717 programs, Xen... 2026-08-15
notable Primary completion moved earlier: 2026-07-15 -> 2023-10-31 2026-08-15
minor Completion pushed: 2027-07-15 -> 2030-09-05 2026-08-15
Trial Details
NCT Number NCT05453799
Lead Sponsor Northwestern University
Collaborators: National Cancer Institute (NCI)
Conditions Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Oncocytic Carcinoma
Enrollment 54 participants
Start Date 2022-07-21
Primary Completion 2023-10-31 (estimated)
Study Completion 2030-09-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-14